Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Macrophage depletion overcomes human hematopoietic cell engraftment failure in zebrafish embryo.

Cell death & disease·2024
Same author

Development of an efficient, ready to use, blood platelet-release device based on two new flow regime parameters: The periodic hydrodynamic loading and the shear stress accumulation.

New biotechnology·2023
Same author

ADP receptor P2Y12 is the capstone of the cross-talk between Ca<sup>2+</sup> mobilization pathways dependent on Ca<sup>2+</sup> ATPases sarcoplasmic/endoplasmic reticulum type 3 and type 2b in platelets.

Research and practice in thrombosis and haemostasis·2023
Same author

Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice.

Blood advances·2022
Same author

Platelet dysfunction and thrombus instability in flow conditions in patients with severe COVID-19.

Thrombosis research·2022
Same author

Treatment of congenital thrombocytopenia and decreased collagen reactivity in G6b-B-deficient mice.

Blood advances·2022

Related Experiment Video

Updated: Jul 6, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

P2 receptors, platelet function and pharmacological implications.

Christian Gachet1

  • 1Institut National de la Santé et de la Recherche Médicale, U311, Strasbourg, France. christian.gachet@efs-alsace.fr

Thrombosis and Haemostasis
|March 11, 2008
PubMed
Summary
This summary is machine-generated.

Platelet receptors P2Y12, P2Y1, and P2X1 are key targets for antithrombotic drugs. Research explores optimizing P2Y12 inhibition and investigates P2Y1 and P2X1 as novel targets for treating thrombosis and inflammation.

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jul 6, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Area of Science:

  • Pharmacology
  • Hematology
  • Molecular Biology

Background:

  • Adenosine diphosphate (ADP) and adenosine triphosphate (ATP) are critical signaling molecules in platelet activation.
  • Platelet P2 receptors, including P2Y12, P2Y1, and P2X1, mediate platelet aggregation and thrombus formation.

Purpose of the Study:

  • To review the role of P2 receptors in platelet function and their potential as targets for antithrombotic therapies.
  • To discuss the established role of the P2Y12 receptor in antithrombotic drug development and the ongoing debate regarding optimal inhibition.
  • To explore P2Y1 and P2X1 receptors as novel targets for antithrombotic agents and their role in inflammation.

Main Methods:

  • Review of existing literature on P2 receptor pharmacology and antithrombotic drug mechanisms.
  • Analysis of studies involving knockout mice for P2Y1 and P2X1 receptors.
  • Examination of data from selective P2Y1 and P2X1 receptor antagonists.

Main Results:

  • The P2Y12 receptor is a validated target for antithrombotic drugs (e.g., clopidogrel, prasugrel, cangrelor), but optimal inhibition remains debated.
  • Studies using P2Y1 and P2X1 knockout models and antagonists indicate these receptors are promising targets for new antithrombotic compounds.
  • P2 receptors also regulate platelet involvement in inflammatory processes.

Conclusions:

  • P2 receptors, particularly P2Y12, P2Y1, and P2X1, are central to platelet activation and thrombosis, offering significant therapeutic potential.
  • Further research into selective antagonism of these receptors could lead to improved antithrombotic strategies with a better efficacy-bleeding profile.
  • Targeting P2 receptors may also offer benefits in managing inflammatory conditions involving platelets.